Immunotherapy with tacrolimus (FK506) does not select for resistance to calcineurin inhibitors in Candida albicans isolates from liver transplant patients.
In Candida albicans, calcineurin mediates tolerance to azole antifungal drugs, survival in serum, and virulence. In this study, we examined 24 Candida isolates from liver transplant recipients receiving a calcineurin inhibitor as a component of their immunosuppressive therapy. We were unable to detect a difference in susceptibility to calcineurin inhibitors in combination with fluconazole, serum, or calcium in these isolates.
Department of Molecular Genetics and Microbiology, 322 CARL Building, Box 3546, Duke University Medical Center, Research Drive, Durham, NC 27710, USA.
Jennifer L
JL
Reedy
Shahid
S
Husain
Michael
M
Ison
Timothy L
TL
Pruett
Nina
N
Singh
Joseph
J
Heitman
D065095:Calcineurin Inhibitors; D002118:Calcium / Q000494:pharmacology; D002176:Candida albicans / Q000187:drug effects*; D025141:Drug Resistance, Fungal; D015725:Fluconazole / Q000494:pharmacology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016031:Liver Transplantation; D044967:Serum / Q000502:physiology; D016559:Tacrolimus / Q000627:therapeutic use*
D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D015725:Fluconazole; D002118:Calcium; D016559:Tacrolimus